<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T20:02:02Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:5009064" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:5009064</identifier><datestamp>2016-09-06</datestamp><setSpec>elsevierwt</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="brief-report">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Cell Rep</journal-id>
      <journal-id journal-id-type="iso-abbrev">Cell Rep</journal-id>
      <journal-title-group>
        <journal-title>Cell Reports</journal-title>
      </journal-title-group>
      <issn pub-type="epub">2211-1247</issn>
      <publisher>
        <publisher-name>Cell Press</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC5009064</article-id>
      <article-id pub-id-type="pmcid">PMC5009064</article-id>
      <article-id pub-id-type="pmc-uid">5009064</article-id>
      <article-id pub-id-type="pmid">27545878</article-id>
      <article-id pub-id-type="publisher-id">S2211-1247(16)31033-6</article-id>
      <article-id pub-id-type="doi">10.1016/j.celrep.2016.07.086</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>SPATA2-Mediated Binding of CYLD to HOIP Enables CYLD Recruitment to Signaling Complexes</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Kupka</surname>
            <given-names>Sebastian</given-names>
          </name>
          <xref rid="aff1" ref-type="aff">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>DeÂ Miguel</surname>
            <given-names>Diego</given-names>
          </name>
          <xref rid="aff1" ref-type="aff">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Draber</surname>
            <given-names>Peter</given-names>
          </name>
          <xref rid="aff1" ref-type="aff">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Martino</surname>
            <given-names>Luigi</given-names>
          </name>
          <xref rid="aff2" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Surinova</surname>
            <given-names>Silvia</given-names>
          </name>
          <xref rid="aff1" ref-type="aff">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rittinger</surname>
            <given-names>Katrin</given-names>
          </name>
          <xref rid="aff2" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Walczak</surname>
            <given-names>Henning</given-names>
          </name>
          <email>h.walczak@ucl.ac.uk</email>
          <xref rid="aff1" ref-type="aff">1</xref>
          <xref rid="fn1" ref-type="fn">3</xref>
          <xref rid="cor1" ref-type="corresp">â</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1"><label>1</label>Centre for Cell Death, Cancer, and Inflammation (CCCI), UCL Cancer Institute, University College London, 72 Huntley Street, London WC1E 6DD, UK</aff>
      <aff id="aff2"><label>2</label>The Francis Crick Institute, 1 Midland Road, London NW1 1BF, UK</aff>
      <author-notes>
        <corresp id="cor1"><label>â</label>Corresponding author <email>h.walczak@ucl.ac.uk</email></corresp>
        <fn id="fn1">
          <label>3</label>
          <p id="ntpara0010">Lead Contact</p>
        </fn>
      </author-notes>
      <pub-date pub-type="pmc-release">
        <day>18</day>
        <month>8</month>
        <year>2016</year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="collection">
        <day>30</day>
        <month>8</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>18</day>
        <month>8</month>
        <year>2016</year>
      </pub-date>
      <volume>16</volume>
      <issue>9</issue>
      <fpage>2271</fpage>
      <lpage>2280</lpage>
      <history>
        <date date-type="received">
          <day>7</day>
          <month>6</month>
          <year>2016</year>
        </date>
        <date date-type="rev-recd">
          <day>6</day>
          <month>7</month>
          <year>2016</year>
        </date>
        <date date-type="accepted">
          <day>29</day>
          <month>7</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Â© 2016 The Authors</copyright-statement>
        <copyright-year>2016</copyright-year>
        <license license-type="CC BY" xlink:href="http://creativecommons.org/licenses/by/4.0/">
          <license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p>
        </license>
      </permissions>
      <abstract id="abs0010">
        <title>Summary</title>
        <p>Recruitment of the deubiquitinase CYLD to signaling complexes is mediated by its interaction with HOIP, the catalytically active component of the linear ubiquitin chain assembly complex (LUBAC). Here, we identify SPATA2 as a constitutive direct binding partner of HOIP that bridges the interaction between CYLD and HOIP. SPATA2 recruitment to TNFR1- and NOD2-signaling complexes is dependent on HOIP, and loss of SPATA2 abolishes CYLD recruitment. Deficiency in SPATA2 exerts limited effects on gene activation pathways but diminishes necroptosis induced by tumor necrosis factor (TNF), resembling loss of CYLD. In summary, we describe SPATA2 as a previously unrecognized factor in LUBAC-dependent signaling pathways that serves as an adaptor between HOIP and CYLD, thereby enabling recruitment of CYLD to signaling complexes.</p>
      </abstract>
      <abstract abstract-type="graphical" id="abs0015">
        <title>Graphical Abstract</title>
        <fig id="undfig1" position="anchor">
          <graphic xlink:href="fx1"/>
        </fig>
      </abstract>
      <abstract abstract-type="author-highlights" id="abs0020">
        <title>Highlights</title>
        <p>
          <list list-type="simple">
            <list-item id="u0010">
              <label>â¢</label>
              <p>SPATA2 bridges the interaction between HOIP and CYLD</p>
            </list-item>
            <list-item id="u0015">
              <label>â¢</label>
              <p>CYLD recruitment to the TNFR1-signaling complex requires SPATA2</p>
            </list-item>
            <list-item id="u0020">
              <label>â¢</label>
              <p>Loss of SPATA2 phenocopies absence of CYLD in TNFR1 signaling</p>
            </list-item>
          </list>
        </p>
      </abstract>
      <abstract abstract-type="teaser" id="abs0025">
        <p>Kupka etÂ al. show that the previously demonstrated interaction of CYLD with HOIP, which is required for recruitment of CYLD into signaling complexes, is indirect and mediated by SPATA2. Loss of SPATA2 abrogates recruitment of CYLD to signaling complexes and consequently mimics CYLD deficiency with regards to gene activation and necroptosis induced by TNF.</p>
      </abstract>
    </article-meta>
    <notes>
      <p id="misc0010">Published: August 18, 2016</p>
    </notes>
  </front>
  <body>
    <sec id="sec1">
      <title>Introduction</title>
      <p>Over the past few years, the balancing roles of E3 ubiquitin ligases (E3s) and deubiquitinases (DUBs) in creating and degrading ubiquitin chains, respectively, have emerged as crucial at regulating innate and adaptive immune responses (<xref rid="bib10" ref-type="bibr">Fiil and Gyrd-Hansen, 2014</xref>, <xref rid="bib42" ref-type="bibr">Zinngrebe etÂ al., 2014</xref>). There are eight different kinds of ubiquitin chains that accomplish different physiological outcomes (<xref rid="bib39" ref-type="bibr">Yau and Rape, 2016</xref>). For example, lysine 48 (K48)-linked chains target proteins for degradation by the proteasome, whereas K63- and methionine 1 (M1)-linked chains (the latter also referred to as linear ubiquitin chains) are involved in the regulation of gene activation pathways and cell death (<xref rid="bib3" ref-type="bibr">Chen and Sun, 2009</xref>, <xref rid="bib16" ref-type="bibr">Iwai etÂ al., 2014</xref>). The differently linked types of ubiquitin chains are generated by specific E3s and are degraded by specialized DUBs. Hence, precise timing of the respective activities of these enzymes is paramount for fine regulation of the signaling output generated by ubiquitin-involving signaling complexes (SCs) (<xref rid="bib3" ref-type="bibr">Chen and Sun, 2009</xref>, <xref rid="bib19" ref-type="bibr">Kupka etÂ al., 2016</xref>, <xref rid="bib42" ref-type="bibr">Zinngrebe etÂ al., 2014</xref>).</p>
      <p>Tumor necrosis factor (TNF) binding to TNF receptor 1 (TNFR1) triggers formation of the TNFR1 signaling complex (TNFR1-SC) (<xref rid="bib36" ref-type="bibr">Walczak etÂ al., 2012</xref>). Signals initiated from this complex result in two very different outcomes: (1) induction ofÂ gene activation via NF-ÎºB and mitogen-activated protein (MAP) kinases and (2) induction of cell death, which can either be apoptotic or necroptotic. Linear ubiquitination, mediated by the linear ubiquitin chain assembly complex (LUBAC), is crucial in deciding the fate of cells upon TNF stimulation. In the absence of LUBAC, the lack of linear ubiquitin chains in the TNFR1-SC results in defective recruitment of various components and complex destabilization (<xref rid="bib12" ref-type="bibr">Haas etÂ al., 2009</xref>). This shifts the signaling toward enhanced formation of a secondary SC, which induces cell death (<xref rid="bib26" ref-type="bibr">Peltzer etÂ al., 2014</xref>), also referred to as complex II of TNFR1 signaling (<xref rid="bib23" ref-type="bibr">Newton and Manning, 2016</xref>). In addition, linear and other ubiquitin linkages are removed by the DUB CYLD, aÂ process that is crucial to enable the formation of complex II, as CYLD- deficient cells are resistant to TNF-induced cell death (<xref rid="bib6" ref-type="bibr">Draber etÂ al., 2015</xref>, <xref rid="bib22" ref-type="bibr">Moquin etÂ al., 2013</xref>).</p>
      <p>LUBAC targets within the TNFR1-SC include RIP1, NEMO, TNFR1, and TRADD (<xref rid="bib6" ref-type="bibr">Draber etÂ al., 2015</xref>, <xref rid="bib11" ref-type="bibr">Gerlach etÂ al., 2011</xref>, <xref rid="bib33" ref-type="bibr">Tokunaga etÂ al., 2011</xref>). Furthermore, LUBAC regulates signaling through various other receptors, including CD40, NOD2, and IL-1R (<xref rid="bib4" ref-type="bibr">Damgaard etÂ al., 2012</xref>, <xref rid="bib9" ref-type="bibr">Emmerich etÂ al., 2013</xref>, <xref rid="bib11" ref-type="bibr">Gerlach etÂ al., 2011</xref>). LUBAC is composed of three subunits: SHARPIN, HOIL-1, and the catalytic component HOIL-1 interacting protein (HOIP) (<xref rid="bib6" ref-type="bibr">Draber etÂ al., 2015</xref>, <xref rid="bib12" ref-type="bibr">Haas etÂ al., 2009</xref>, <xref rid="bib15" ref-type="bibr">Ikeda etÂ al., 2011</xref>, <xref rid="bib17" ref-type="bibr">Kirisako etÂ al., 2006</xref>, <xref rid="bib33" ref-type="bibr">Tokunaga etÂ al., 2011</xref>). Additionally, LUBAC is associated with two DUBs: CYLD and OTULIN (<xref rid="bib6" ref-type="bibr">Draber etÂ al., 2015</xref>, <xref rid="bib8" ref-type="bibr">Elliott etÂ al., 2014</xref>, <xref rid="bib31" ref-type="bibr">Takiuchi etÂ al., 2014</xref>). Interaction of OTULIN and CYLD with HOIP is mutually exclusive (<xref rid="bib6" ref-type="bibr">Draber etÂ al., 2015</xref>). Although CYLD is co-recruited into signaling complexes via HOIP, OTULIN is not (<xref rid="bib6" ref-type="bibr">Draber etÂ al., 2015</xref>). The mechanistic explanation for this observation remains elusive, yet together, these findings point toward specific and distinct functions for OTULIN versus CYLD in regulating LUBAC.</p>
      <p>Intriguingly, although the interaction of OTULIN with HOIP has been shown to be direct and was structurally characterized (<xref rid="bib8" ref-type="bibr">Elliott etÂ al., 2014</xref>, <xref rid="bib29" ref-type="bibr">Schaeffer etÂ al., 2014</xref>), we were not able toÂ detect direct binding of CYLD to HOIP. This suggested the existence of (an) additional factor(s) mediating this interaction. The search for such a factor resulted in the discovery of SPATA2 as a previously unrecognized component of the TNFR1-SC and NOD2-SC, which bridges the interaction between CYLD and HOIP by directly interacting, via distinct domains, with both proteins.</p>
    </sec>
    <sec id="sec2">
      <title>Results</title>
      <sec id="sec2.1">
        <title>SPATA2 Is a Component of the TNFR1-SC</title>
        <p>To address whether there may be factors, in addition to CYLD, that are constitutively associated with LUBAC and recruited to the TNFR1-SC, we performed two different mass spectrometry (MS) analyses using a modified tandem affinity purification (TAP) approach. In the first one, we employed TAP-tagged TNF (TAP-TNF) to identify components of the TNFR1-SC and in the second one we expressed TAP-tagged HOIP (HOIP-TAP). CYLD, and the other two LUBAC components, HOIL-1 and SHARPIN, served as positive controls in this analysis; indeed, all three factors were identified in both proteomic approaches as high-scoring interactors. SPATA2 was an additional protein that was identified by both proteomic approaches (<xref rid="fig1" ref-type="fig">Figures 1</xref>A and 1B; <xref rid="mmc1" ref-type="supplementary-material">Tables S1</xref> and <xref rid="mmc2" ref-type="supplementary-material">S2</xref>). Thus, SPATA2 was a candidate for a constitutive interaction partner of LUBAC and for a previously unrecognized component of the TNFR1-SC.</p>
        <p>We validated the constitutive interaction of SPATA2 with HOIP by western blotting (<xref rid="fig1" ref-type="fig">FigureÂ 1</xref>C). When examining whether SPATA2 formed part of the native TNFR1-SC, we found that it was recruited to this complex. In line with the constitutive interaction between SPATA2 and LUBAC, this occurred with kinetics similar to those of HOIP and CYLD (<xref rid="fig1" ref-type="fig">FigureÂ 1</xref>D). Hence, SPATA2 is a previously unrecognized component of the native TNFR1-SC and a constitutive interaction partner of LUBAC.</p>
      </sec>
      <sec id="sec2.2">
        <title>SPATA2 Recruitment to the TNFR1- and NOD2-SC Requires HOIP</title>
        <p>We next tested whether SPATA2 was recruited to the TNFR1-SC due to its constitutive interaction with HOIP, in a manner similar to CYLD (<xref rid="bib6" ref-type="bibr">Draber etÂ al., 2015</xref>). This analysis revealed that SPATA2 was absent from the TNFR1-SC in HOIP-deficient A549 cells (<xref rid="fig2" ref-type="fig">FigureÂ 2</xref>A), indicating that recruitment of SPATA2 is dependent on HOIP.</p>
        <p>Despite the constitutive interaction between SPATA2 and LUBAC, it was possible that linear ubiquitination could be required for its recruitment to, or retention in, the TNFR1-SC. This was, however, not the case, as SPATA2 recruitment was unaltered in HOIP-deficient A549 cells reconstituted with an inactive form of HOIP (HOIP-C885S) (<xref rid="fig2" ref-type="fig">FigureÂ 2</xref>B). Hence, SPATA2 recruitment to the TNFR1-SC requires LUBAC, but not its catalytic activity.</p>
        <p>We previously showed that, in addition to the TNFR1-SC, LUBAC also forms part of various other signaling complexes, including the NOD2-SC (<xref rid="bib4" ref-type="bibr">Damgaard etÂ al., 2012</xref>, <xref rid="bib6" ref-type="bibr">Draber etÂ al., 2015</xref>, <xref rid="bib11" ref-type="bibr">Gerlach etÂ al., 2011</xref>, <xref rid="bib12" ref-type="bibr">Haas etÂ al., 2009</xref>). We therefore tested whether SPATA2 is also recruited to the NOD2-SC and, if so, whether its recruitment requires HOIP. When stimulating A549 cells expressing FLAG-tagged NOD2 with L18-MDP and purifying the resulting signaling complex, we found that SPATA2 was readily recruited alongside HOIP and CYLD (<xref rid="fig2" ref-type="fig">FigureÂ 2</xref>C). Importantly, SPATA2, like CYLD, was not recruited to the NOD2-SC in cells devoid of HOIP (<xref rid="fig2" ref-type="fig">FigureÂ 2</xref>C). Hence, SPATA2 forms part of the NOD2-SC, and its recruitment is a result of its constitutive interaction with LUBAC via HOIP.</p>
      </sec>
      <sec id="sec2.3">
        <title>SPATA2 Is Required for Recruitment of CYLD to the TNFR1-SC</title>
        <p>Comparison of protein levels in different knockout cells showed that SPATA2 levels were drastically reduced in HeLa cells deficient in CYLD but not in cells deficient in OTULIN or HOIP (<xref rid="fig3" ref-type="fig">FigureÂ 3</xref>A). This suggested that CYLD and SPATA2 might be functionally connected and possibly interact with each other.</p>
        <p>Previous data showed that the USP domain of CYLD is associated with the PUB domain of HOIP (<xref rid="bib31" ref-type="bibr">Takiuchi etÂ al., 2014</xref>). However, we could not detect a direct interaction between these domains by isothermal titration calorimetry (ITC) (<xref rid="fig3" ref-type="fig">FigureÂ 3</xref>B). Additionally, when we overexpressed CYLD in HOIP-TAP-expressing cells, we found that overexpression only marginally increased the amount of CYLD bound to HOIP as compared to endogenous levels of CYLD (<xref rid="fig3" ref-type="fig">FigureÂ 3</xref>C). This is in stark contrast to the interaction of HOIP with OTULIN, which was substantially increased by OTULIN overexpression (<xref rid="fig3" ref-type="fig">FigureÂ 3</xref>C). This suggested that the interaction between HOIP andÂ CYLD is mediated by an additional factor, and we were therefore prompted to test whether SPATA2 may function asÂ an adaptor. If this were the case, the interaction of HOIP and CYLD should increase as a function of co-overexpressionÂ ofÂ SPATA2. Strikingly, the association of CYLD with HOIP drastically increased when SPATA2 was also overexpressed (<xref rid="fig3" ref-type="fig">FigureÂ 3</xref>C). Accordingly, when we reduced SPATA2 levels by RNAi and immunoprecipitated overexpressed FLAG-tagged HOIP, the amount of CYLD associated with HOIP was drastically decreased (<xref rid="fig3" ref-type="fig">FigureÂ 3</xref>D).</p>
        <p>We next tested whether SPATA2 is required for recruitment of CYLD to the TNFR1-SC. Analysis of the TNFR1-SC showed that, compared to control cells, CYLD was virtually absent from the TNFR1-SC that formed in cells in which SPATA2 expression was suppressed by RNAi (<xref rid="fig3" ref-type="fig">FigureÂ 3</xref>E). Together, this demonstrates that SPATA2 serves as an adaptor between CYLD and HOIP and that SPATA2 is required and sufficient for recruitment of CYLD, via HOIP, to the TNFR1-SC.</p>
      </sec>
      <sec id="sec2.4">
        <title>The N Terminus of SPATA2 Interacts with the USP Domain of CYLD, whereas Its C Terminus Binds to the PUB Domain of HOIP</title>
        <p>We and others previously showed that the (PUB)-domain of HOIP is essential for recruitment of CYLD (<xref rid="bib6" ref-type="bibr">Draber etÂ al., 2015</xref>, <xref rid="bib8" ref-type="bibr">Elliott etÂ al., 2014</xref>). To test whether SPATA2 interacts with thisÂ domain, we reconstituted HOIP-deficient K562 cells with FLAG-tagged truncated versions of HOIP and immunoprecipitated the associated complex. This revealed that only constructs encompassing the N-terminal PUB domain bound SPATA2 (<xref rid="fig4" ref-type="fig">FigureÂ 4</xref>A). Additionally, we used a HOIP-PUB domain point mutant (N102A), which abolishes the interaction of both OTULIN and CYLD with HOIP (<xref rid="bib6" ref-type="bibr">Draber etÂ al., 2015</xref>, <xref rid="bib8" ref-type="bibr">Elliott etÂ al., 2014</xref>). Importantly, this mutant was also unable to restore SPATA2 recruitment to the TNFR1-SC (<xref rid="fig4" ref-type="fig">FigureÂ 4</xref>B). Together, these data indicate that the PUB domain of HOIP is essential for the interaction withÂ SPATA2 and, consequently, for recruitment of CYLD to the TNFR1-SC.</p>
        <p>To characterize the interaction of SPATA2 with CYLD and HOIP further, we expressed various deletion mutants of SPATA2 with a GFP tag. Immunoprecipitation of these truncated forms of SPATA2 revealed that the interaction with CYLD is mediated by the N terminus of SPATA2 as a fragment comprising amino acids 1â116 was sufficient to bind to CYLD (<xref rid="fig4" ref-type="fig">FigureÂ 4</xref>C). InÂ contrast, only SPATA2 fragments comprising amino acids 167â417 bound to HOIP (<xref rid="fig4" ref-type="fig">FigureÂ 4</xref>C).</p>
      </sec>
      <sec id="sec2.5">
        <title>SPATA2 Contains a PIM that Mediates the Interaction with the PUB Domain of HOIP</title>
        <p>Because the N102A mutation in the PUB domain of HOIP abolishes the interaction with OTULIN and SPATA2, we assumed that, similar to OTULIN, SPATA2 might also contain a PUB-domain interacting motif (PIM). To precisely map the interacting peptide, we designed a peptide array, spotted on a nitrocellulose membrane, composed of 20-mer peptides that overlap by one amino acid and span amino acids 201â520 of SPATA2. Incubation with glutathione S-transferase (GST) or GST-tagged PUB domain of HOIP identified that SPATA2 peptides corresponding to amino acids 319â347 interacted specifically with HOIPâs PUB domain (<xref rid="fig4" ref-type="fig">FigureÂ 4</xref>D). The overlapping sequence between interacting peptides suggests RGTYFSTQDDVDLYTDSEPR as the PIM of SPATA2. Characterization of the interaction by ITC revealed an affinity of 0.9Â Î¼M (<xref rid="fig4" ref-type="fig">FigureÂ 4</xref>E). Additionally, sequence alignment of this PIM from different species revealed a high degree of evolutionary conservation (<xref rid="fig4" ref-type="fig">FigureÂ 4</xref>F).</p>
        <p>Together, these results show that SPATA2 contains two distinct domains that are responsible for mediating the interaction with CYLD and HOIP, respectively; while the N terminus of SPATA2 binds to the USP domain of CYLD, the interaction with HOIP is mediated via a highly conserved PIM located in the central portion of SPATA2, which is recognized by the PUB domain of HOIP.</p>
      </sec>
      <sec id="sec2.6">
        <title>SPATA2 or CYLD Deficiency has Limited Effects on TNF-Induced Gene Activatory Pathways</title>
        <p>We next examined how SPATA2 knockdown affected TNF-induced gene activation. To do so, we employed wild-type and CYLD-deficient HeLa cells and depleted SPATA2 by RNAi before stimulating these cells with TNF. This analysis revealed no increase in the activation of NF-ÎºB in SPATA2-depleted as compared to control cells, whereas activation of c-Jun N-terminal kinase (JNK) was only slightly increased (<xref rid="fig5" ref-type="fig">FigureÂ 5</xref>A). However, the same was true for CYLD-deficient cells, and, importantly, no further increase was seen by concomitant SPATA2 suppression (<xref rid="fig5" ref-type="fig">FigureÂ 5</xref>A). Similarly, RNAi-mediated suppression of SPATA2 in A549 cells did not increase TNF-induced activation of NF-ÎºB, but it did increase activation of JNK (<xref rid="fig5" ref-type="fig">FigureÂ 5</xref>B). Because CYLD deficiency is generally assumed to significantly affect TNF-induced NF-ÎºB activation, we also stimulated primary bone-marrow-derived macrophages (BMDMs) with TNF and analyzed activation of JNK, extracellular signal-regulated kinase (ERK), and NF-ÎºB. In line with our observation in cell lines, however, no difference in NF-ÎºB activation could be detected between CYLD-proficient and CYLD-deficient BMDMs, whereas deficiency in CYLD resulted in a slight increase in JNK and ERK activation in these cells (<xref rid="fig5" ref-type="fig">FigureÂ 5</xref>C). Thus, in all cell types we tested, SPATA2 or CYLD deficiency had little if any effect on TNF-induced NF-ÎºB activation but slightly increased JNK activation.</p>
      </sec>
      <sec id="sec2.7">
        <title>SPATA2 Deficiency Diminishes TNF-Induced Necroptosis</title>
        <p>In addition to its proposed role in inhibiting gene activation induced by various ligands, CYLD has been shown to enhance TNF-mediated cell death. More specifically, necroptosis was shown to require CYLD in L929 cells (<xref rid="bib14" ref-type="bibr">Hitomi etÂ al., 2008</xref>, <xref rid="bib22" ref-type="bibr">Moquin etÂ al., 2013</xref>, <xref rid="bib24" ref-type="bibr">OâDonnell etÂ al., 2011</xref>). To test whether SPATA2 was also required for necroptosis, we reduced SPATA2 or CYLD expression in the murine cell line L929 using small interfering RNA (siRNA) (<xref rid="fig5" ref-type="fig">Figures 5</xref>D and 5E) and stimulated these cells with TNF/zVAD to induce necroptosis. This revealed that knockdown of SPATA2 protected L929 cells from TNF/zVAD-induced necroptosis to a similar extent as CYLD knockdown (<xref rid="fig5" ref-type="fig">FigureÂ 5</xref>D). Thus, like CYLD, SPATA2 serves as a factor that enables TNF-induced cell death.</p>
      </sec>
    </sec>
    <sec id="sec3">
      <title>Discussion</title>
      <p>We previously showed that CYLD recruitment to the TNFR1-SC requires HOIP (<xref rid="bib6" ref-type="bibr">Draber etÂ al., 2015</xref>). Here, we show that SPATA2 is indispensable for CYLD recruitment to this complex by bridging CYLD and HOIP. Like OTULIN, SPATA2 directly binds to the PUB domain of HOIP, and their interactions are mutually exclusive. Because SPATA2 also requires HOIP for its recruitment to the NOD2-SC, we deem it likely that the complex consisting of LUBAC, SPATA2, and CYLD is the default complex recruited also to other receptor-associated complexes known to involve CYLD and/or LUBAC (<xref rid="bib5" ref-type="bibr">Douanne etÂ al., 2016</xref>, <xref rid="bib32" ref-type="bibr">Tauriello etÂ al., 2010</xref>). Given the growing relevance of the equilibrium between ubiquitination and deubiquitination in the regulation of signaling complexes (<xref rid="bib13" ref-type="bibr">Harhaj and Dixit, 2012</xref>, <xref rid="bib19" ref-type="bibr">Kupka etÂ al., 2016</xref>, <xref rid="bib39" ref-type="bibr">Yau and Rape, 2016</xref>) and the involvement of CYLD in a wide number of signaling platforms (<xref rid="bib6" ref-type="bibr">Draber etÂ al., 2015</xref>, <xref rid="bib21" ref-type="bibr">Mathis etÂ al., 2015</xref>, <xref rid="bib27" ref-type="bibr">Reiley etÂ al., 2006</xref>, <xref rid="bib32" ref-type="bibr">Tauriello etÂ al., 2010</xref>, <xref rid="bib41" ref-type="bibr">Zhang etÂ al., 2011</xref>), the discovery of SPATA2 as a previously unrecognized adaptor between CYLD and HOIP by us and others (<xref rid="bib35" ref-type="bibr">Wagner etÂ al., 2016</xref>) provides additional insight on the mechanisms by which thisÂ DUB controls the outcome of these diverse signaling processes.</p>
      <p>TNF-stimulated signaling induces gene activation pathways and, under certain circumstances, programmed cell death (<xref rid="bib30" ref-type="bibr">Sedger and McDermott, 2014</xref>, <xref rid="bib37" ref-type="bibr">Wertz, 2014</xref>). Here, we show that in absence of SPATA2, CYLD is not recruited to the TNFR1-SC. Therefore, absence of SPATA2 should affect TNF-induced signaling in a manner similar to the absence of CYLD. Previous studies reported the importance of CYLD for induction of necroptosis (<xref rid="bib14" ref-type="bibr">Hitomi etÂ al., 2008</xref>, <xref rid="bib22" ref-type="bibr">Moquin etÂ al., 2013</xref>, <xref rid="bib24" ref-type="bibr">OâDonnell etÂ al., 2011</xref>). In line, siRNA-mediated knockdown of SPATA2 or CYLD protected cells from TNF-induced necroptosis to a similar extent, Likewise, suppression of SPATA2 correlated with that of CYLD regarding gene activation pathways, exerting minor effects on TNF-induced NF-ÎºB activation but showing a slight effect on JNK activation in the different cell types tested. This is in apparent contrast to the accepted role of CYLD as a negative regulator of NF-ÎºB activation and results presented on the role of SPATA2 in gene activation while our study was under review (<xref rid="bib35" ref-type="bibr">Wagner etÂ al., 2016</xref>). It should be noted, however, that most studies investigating the role of CYLD in NF-ÎºB activation were performed using overexpression models and/or luciferase reporter assays, mostly in HEK293 cells (<xref rid="bib2" ref-type="bibr">Brummelkamp etÂ al., 2003</xref>, <xref rid="bib18" ref-type="bibr">Kovalenko etÂ al., 2003</xref>, <xref rid="bib34" ref-type="bibr">Trompouki etÂ al., 2003</xref>). The physiological relevance of these results is at least arguable, since they are based on artificial and isolated reporter elements. Indeed, luciferase reporter assays have already been described to be unreliable under certain circumstances, specifically in HEK293 cells (<xref rid="bib20" ref-type="bibr">Ling etÂ al., 2012</xref>). In fact, several studies previously reported only minimal effects of CYLD deficiency on TNF-induced gene activation in general and a slight increase of JNK activation (<xref rid="bib22" ref-type="bibr">Moquin etÂ al., 2013</xref>, <xref rid="bib27" ref-type="bibr">Reiley etÂ al., 2006</xref>, <xref rid="bib40" ref-type="bibr">Zhang etÂ al., 2006</xref>). Together, it appears that the role of CYLD withÂ respect to gene activation is certainly more cell-type andÂ pathway dependent than currently thought. Our results on SPATA2 and CYLD, in connection with the previous literature on CYLD, provide the rationale for a thorough reassessment of the effects of deficiency in CYLD, and now also of SPATA2, on gene activation induced by different stimuli and in different cell types.</p>
      <p>Initially, SPATA2 was described as a protein that might beÂ involved in spermatogenesis, as it is highly expressed in testis and strongly upregulated during spermatogenesis (<xref rid="bib25" ref-type="bibr">Onisto etÂ al., 2001</xref>). Interestingly, CYLD-deficient mice, despite having no overt phenotype, have been reported to show defects in spermatogenesis (<xref rid="bib38" ref-type="bibr">Wright etÂ al., 2007</xref>). In light of our result that CYLD-deficient cells have drastically reduced SPATA2 levels, it is possible that these defects are due to SPATA2 deficiency. It will be interesting to investigate the connection between CYLD and SPATA2 with regards to defects in spermatogenesis, i.e., whether in this context the function of SPATA2 is CYLD dependent.</p>
      <p>The observation that SPATA2 plays an important role in CYLD function could be of clinical relevance, as patients with mutations in CYLD develop cylindromatosis (<xref rid="bib1" ref-type="bibr">Biggs etÂ al., 1995</xref>). A first analysis of the publicly available databases for autoimmune patients did not reveal any overt polymorphisms in the SPATA2 gene. However, it is possible that SPATA2 mutations could be involved in patients suffering from cylindromatosis or related diseases who do not have mutations in CYLD and for whom a molecular explanation is consequently still missing (<xref rid="bib7" ref-type="bibr">Dubois etÂ al., 2015</xref>, <xref rid="bib28" ref-type="bibr">Saggar etÂ al., 2008</xref>).</p>
    </sec>
    <sec id="sec4">
      <title>Experimental Procedures</title>
      <sec id="sec4.1">
        <title>Plasmids and Cloning</title>
        <p>SPATA2 was cloned from cDNA by conventional PCR using 5â²-atggggaagcccagttca-3â² as the forward and 5â²-ctatctgtacacgagatgggagag-3â² as the reverse target sequence. HOIP and CYLD expression constructs were described previously (<xref rid="bib6" ref-type="bibr">Draber etÂ al., 2015</xref>).</p>
      </sec>
      <sec id="sec4.2">
        <title>SDS-PAGE, Western Blot, and Antibodies</title>
        <p>Proteins were separated on 4%â15% Mini-PROTEAN TGX Precast Gels with TGX running buffer. Proteins were transferred onto 0.2Â Î¼M nitrocellulose membrane (Bio-Rad, Trans-Blot Turbo Mini Nitrocellulose Transfer Packs). Proteins were detected via western blot using the following antibodies: SPATA2 (Abcam, ab56565), SPATA2 (Bethyl Laboratories, A302-494A), HOIP (Aviva System Biology, ARP43241_P050), SHARPIN (Proteintech, 14626-I-AP), HOIL-1 (<xref rid="bib12" ref-type="bibr">Haas etÂ al., 2009</xref>), CYLD (Santa Cruz Biotechnology, sc-74435), OTULIN (Abcam, ab151117), RIP1 (BD, 610459), TNFR1 (Santa Cruz, 8436), M1-Ub (Merck Millipore, MABS199), IÎºBÎ± (Cell Signaling Technology, 9242), pIÎºBÎ± (Cell Signaling, 9246S), pP65 (Cell Signaling, 7F1), pErk (Santa Cruz, SC-7383), pP38 (Cell Signaling, D3F9), pJNK (Cell Signaling, 98F2), Actin (Sigma-Aldrich, A1978), GAPDH (Abcam, ab8245), FLAG (Sigma-Aldrich, M2), and GST (Cell Signaling, 2622).</p>
      </sec>
      <sec id="sec4.3">
        <title>Production of Recombinant TNF</title>
        <p>The coding sequences of TAP-TNF, consisting of a His-tag followed by 3x FLAG tag, a PreScission cleavage site, and a 2x Strep-tag II, and the extracellular portion of TNF (aa 78â233) or His-TNF (aa 78â233) were inserted in pQE30 vector. Protein was expressed in BL21 (DE3) cells with 1Â mM isopropyl Î²-D-1-thiogalactopyranoside (IPTG) overnight and purified by affinity chromatography on His GraviTrap TALON columns (GE Healthcare), eluted with 500Â mM imidazole and dialyzed against storage buffer (50Â mM Tris [pH 7.4], 100Â mM NaCl, 0.02% Tween, 2Â mM DTT, and 0.5Â M arginine). Protein concentration was determined with a Nanodrop 2000 (Thermo Scientific) and samples were stored at â20Â°C.</p>
      </sec>
      <sec id="sec4.4">
        <title>Transient Transfection</title>
        <p>Cells were seeded the day before and allowed to reach â¼70% confluency on the day of transfection. For a six-well plate, 1Â Î¼g DNA was used per well. First, DNA was diluted in 100Â Î¼l Opti-MEM medium, and TurboFect transfection reagent (Thermo Scientific) or Lipofectamine 2000 (Thermo Fisher) was added in a 1:3 DNA/transfection reagent ratio. After a 30Â min of incubation, the mixture was added dropwise to the cells. Cells were allowed to grow for another day before use for experiments.</p>
      </sec>
      <sec id="sec4.5">
        <title>siRNA-Mediated Knockdown</title>
        <p>Transient knockdown was performed by reverse transfection of cells with siRNA using Lipofectamine 2000 (Invitrogen) following the manufacturerâs recommendations. In summary, Lipofectamine 2000 was added to medium free of FCS and antibiotics and incubated for 20Â min at room temperature. Next, siRNA was added and left at room temperature for 30Â min. The reaction mix was then added dropwise to the cells, and the final volume was adjusted with antibiotic free medium. The ratio of Lipofectamine/siRNA was 3Â Î¼l/Î¼g siRNA in all cases. All experiments were carried out at least 48Â hr after the reverse transfection.</p>
      </sec>
      <sec id="sec4.6">
        <title>Immunoprecipitation of Protein Complexes</title>
        <p>For immunoprecipitation of ectopically expressed tagged proteins, cells were lysed in immunoprecipitation (IP)-lysis buffer and lysate was cleared by centrifugation. FLAG-tagged proteins were immunoprecipitated using anti-FLAG (M2) beads (Sigma-Aldrich). Where other antibodies have been used, 1Â Î¼g antibody was bound to Protein A/G beads (Santa Cruz Biotechnology) prior to the addition to the lysate. Immunoprecipitations were carried out at 4Â°C with gentle rotation for 4â16Â hr. Beads were then washed three times with lysis buffer and reduced using LDS sample buffer.</p>
      </sec>
      <sec id="sec4.7">
        <title>TNFR1-SC Purification</title>
        <p>FLAG-tagged TNF (1Â Î¼g/ml) in medium (37Â°C) was added to the cells for the indicated time. Cells were left in the incubator during the course of stimulation. Subsequently, stimulation medium was aspirated and cells were washed with cold PBS. Cells were lysed in IP-lysis buffer and cellular debris was cleared by centrifugation at 13,000Â rpm for 20Â min. 1/100 of the amount of FLAG-TNF used for the stimulation was added to lysates from non-stimulated cells as a negative control. 10Â Î¼g M2 beads (Sigma-Aldrich) were then added to the lysate and incubated overnight at 4Â°C. The next day, samples were washed three times with IP buffer and then reduced in sample buffer.</p>
      </sec>
      <sec id="sec4.8">
        <title>Mass Spectrometric Analysis of Immunoprecipitated Complexes</title>
        <p>Protein complexes were processed and analyzed as in <xref rid="bib6" ref-type="bibr">Draber etÂ al. (2015)</xref>. In brief, protein mixtures were denatured, reduced, alkylated, and digested with Lys-C and Trypsin. Desalted samples were analyzed by nLC-MS/MS on a Q Exactive Orbitrap coupled to an Easy-nLC 1000 (Thermo Scientific).</p>
      </sec>
      <sec id="sec4.9">
        <title>Isolation of Bone-Marrow-Derived Macrophages</title>
        <p>For preparation of BMDMs, 8-week-old mice were sacrificed. Hindlimbs were removed, and bones were separated from muscle tissue. Femur and tibia were opened on each site, and bone marrow was flushed out using a 25G needle and syringe. Cells were then resuspended in RPMI medium containing 10% fetal calf serum (FCS), 1% penicillin/streptomycin (Invitrogen), and 10% conditioned medium from L929 cells and passed through a cell strainer. Subsequently, cells were plated in a 12-well plate. The conditioned medium was replaced every 2Â days, and cells were incubated for 7Â days before the experiment.</p>
      </sec>
      <sec id="sec4.10">
        <title>Cell Death Analysis</title>
        <p>Cells were treated with 200Â ng/ml TNF or in combination with 20Â Î¼M zVAD-fmk (Abcam) and/or 10Â Î¼M Nec-1Â s (Biovision) for 24Â hr. Supernatant was collected and remaining live cells were trypsinized. Supernatant and detached cells were combined and centrifuged at 2,500Â rpm for 10Â min. The pellet was then resuspended in PBS containing 5Â Î¼g/ml propidium iodide (Sigma). Cells were analyzed by FACS (BD Accuri C6 or Fortessa). Data are presented as mean Â± SEM (nÂ = 3), and statistics were performed using t tests.</p>
      </sec>
      <sec id="sec4.11">
        <title>Peptide Arrays</title>
        <p>Peptide arrays covering residues 200â520 of SPATA2 as a series of 20-mer overlapping peptides were synthesized by the Peptide Chemistry Science Technology Platform of the Francis Crick Institute. Arrays were activated with 70% ethanol for 15Â min and blocked with 5% milk powder in PBS containing 0.05% Tween-20 (PBST). After blocking, the membranes were washed three times with PBST. Recombinant GST or GST-PUB-HOIP in PBST containing 2.5% BSA was added to the respective membrane. The blots were incubated for 1Â hr at room temperature with gentle agitation, washed three times with PBST, and subsequently incubated with anti-GST primary antibody and detected with horseradish peroxidase (HRP)-coupled anti-rabbit antibody.</p>
      </sec>
      <sec id="sec4.12">
        <title>Isothermal Titration Calorimetry</title>
        <p>ITC experiments were performed at 293 K using an ITC-200 microcalorimeter (Malvern Instruments). The protein and peptide solutions were prepared in 25Â mM HEPES (pH 7.5), 150Â mM NaCl, and 0.5Â mM TCEP. Titrations were performed by titrating 20 times 2Â Î¼l HOIP-PUB domain (597Â Î¼M) into the OTULIN peptide (AEHEEDMYRA) at 58Â Î¼M, 398Â Î¼M HOIP-PUB domain into the CYLD-USP domain at 40Â Î¼M, and 500Â Î¼M HOIP-PUB domain into the SPATA2 peptide (RGTYFSTQDDVDLYTDSEPR) at 50Â Î¼M. Integrated heats corrected for heats of dilution were fitted using a 1:1 binding model in the MicroCal-Origin 7.0 software package.</p>
      </sec>
      <sec id="sec4.13">
        <title>Statistical Procedures</title>
        <p>Where indicated, data from at least three biological replicates are presented asÂ mean Â± SEM. Statistical significance was calculated by performing a two-tailed, unpaired Studentâs t test, with <sup>ââ</sup> indicating p â¤ 0.01.</p>
      </sec>
    </sec>
    <sec id="sec5">
      <title>Author Contributions</title>
      <p>H.W. conceived the project. S.K., D.D.M., and H.W. designed the research and wrote the manuscript. S.K., D.D.M., P.D., and L.M performed experiments. S.S. performed mass spectrometric analysis. K.R. conceived and provided the peptide array.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="bib1">
        <element-citation publication-type="journal" id="sref1">
          <person-group person-group-type="author">
            <name>
              <surname>Biggs</surname>
              <given-names>P.J.</given-names>
            </name>
            <name>
              <surname>Wooster</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Ford</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Chapman</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Mangion</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Quirk</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Easton</surname>
              <given-names>D.F.</given-names>
            </name>
            <name>
              <surname>Burn</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Stratton</surname>
              <given-names>M.R.</given-names>
            </name>
          </person-group>
          <article-title>Familial cylindromatosis (turban tumour syndrome) gene localised to chromosome 16q12-q13: evidence for its role as a tumour suppressor gene</article-title>
          <source>Nat. Genet.</source>
          <volume>11</volume>
          <year>1995</year>
          <fpage>441</fpage>
          <lpage>443</lpage>
          <pub-id pub-id-type="pmid">7493027</pub-id>
        </element-citation>
      </ref>
      <ref id="bib2">
        <element-citation publication-type="journal" id="sref2">
          <person-group person-group-type="author">
            <name>
              <surname>Brummelkamp</surname>
              <given-names>T.R.</given-names>
            </name>
            <name>
              <surname>Nijman</surname>
              <given-names>S.M.</given-names>
            </name>
            <name>
              <surname>Dirac</surname>
              <given-names>A.M.</given-names>
            </name>
            <name>
              <surname>Bernards</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB</article-title>
          <source>Nature</source>
          <volume>424</volume>
          <year>2003</year>
          <fpage>797</fpage>
          <lpage>801</lpage>
          <pub-id pub-id-type="pmid">12917690</pub-id>
        </element-citation>
      </ref>
      <ref id="bib3">
        <element-citation publication-type="journal" id="sref3">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>Z.J.</given-names>
            </name>
            <name>
              <surname>Sun</surname>
              <given-names>L.J.</given-names>
            </name>
          </person-group>
          <article-title>Nonproteolytic functions of ubiquitin in cell signaling</article-title>
          <source>Mol. Cell</source>
          <volume>33</volume>
          <year>2009</year>
          <fpage>275</fpage>
          <lpage>286</lpage>
          <pub-id pub-id-type="pmid">19217402</pub-id>
        </element-citation>
      </ref>
      <ref id="bib4">
        <element-citation publication-type="journal" id="sref4">
          <person-group person-group-type="author">
            <name>
              <surname>Damgaard</surname>
              <given-names>R.B.</given-names>
            </name>
            <name>
              <surname>Nachbur</surname>
              <given-names>U.</given-names>
            </name>
            <name>
              <surname>Yabal</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Wong</surname>
              <given-names>W.W.</given-names>
            </name>
            <name>
              <surname>Fiil</surname>
              <given-names>B.K.</given-names>
            </name>
            <name>
              <surname>Kastirr</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Rieser</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Rickard</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Bankovacki</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Peschel</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>The ubiquitin ligase XIAP recruits LUBAC for NOD2 signaling in inflammation and innate immunity</article-title>
          <source>Mol. Cell</source>
          <volume>46</volume>
          <year>2012</year>
          <fpage>746</fpage>
          <lpage>758</lpage>
          <pub-id pub-id-type="pmid">22607974</pub-id>
        </element-citation>
      </ref>
      <ref id="bib5">
        <element-citation publication-type="journal" id="sref5">
          <person-group person-group-type="author">
            <name>
              <surname>Douanne</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Gavard</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>BidÃ¨re</surname>
              <given-names>N.</given-names>
            </name>
          </person-group>
          <article-title>The paracaspase MALT1 cleaves the LUBAC subunit HOIL1 during antigen receptor signaling</article-title>
          <source>J.Â Cell Sci.</source>
          <volume>129</volume>
          <year>2016</year>
          <fpage>1775</fpage>
          <lpage>1780</lpage>
          <pub-id pub-id-type="pmid">27006117</pub-id>
        </element-citation>
      </ref>
      <ref id="bib6">
        <element-citation publication-type="journal" id="sref6">
          <person-group person-group-type="author">
            <name>
              <surname>Draber</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Kupka</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Reichert</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Draberova</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Lafont</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>de Miguel</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Spilgies</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Surinova</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Taraborrelli</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Hartwig</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>LUBAC-recruited CYLD and A20 regulate gene activation and cell death by exerting opposing effects on linear ubiquitin in signaling complexes</article-title>
          <source>Cell Rep.</source>
          <volume>13</volume>
          <year>2015</year>
          <fpage>2258</fpage>
          <lpage>2272</lpage>
          <pub-id pub-id-type="pmid">26670046</pub-id>
        </element-citation>
      </ref>
      <ref id="bib7">
        <element-citation publication-type="journal" id="sref7">
          <person-group person-group-type="author">
            <name>
              <surname>Dubois</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Wilson</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Bourn</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Rajan</surname>
              <given-names>N.</given-names>
            </name>
          </person-group>
          <article-title>&lt;i&gt;CYLD&lt;/i&gt; Genetic testing for Brooke-Spiegler syndrome, familial cylindromatosis and multiple familial trichoepitheliomas</article-title>
          <source>PLoS Curr.</source>
          <volume>7</volume>
          <year>2015</year>
          <fpage>7</fpage>
        </element-citation>
      </ref>
      <ref id="bib8">
        <element-citation publication-type="journal" id="sref8">
          <person-group person-group-type="author">
            <name>
              <surname>Elliott</surname>
              <given-names>P.R.</given-names>
            </name>
            <name>
              <surname>Nielsen</surname>
              <given-names>S.V.</given-names>
            </name>
            <name>
              <surname>Marco-Casanova</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Fiil</surname>
              <given-names>B.K.</given-names>
            </name>
            <name>
              <surname>Keusekotten</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Mailand</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Freund</surname>
              <given-names>S.M.</given-names>
            </name>
            <name>
              <surname>Gyrd-Hansen</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Komander</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>Molecular basis and regulation of OTULIN-LUBAC interaction</article-title>
          <source>Mol. Cell</source>
          <volume>54</volume>
          <year>2014</year>
          <fpage>335</fpage>
          <lpage>348</lpage>
          <pub-id pub-id-type="pmid">24726323</pub-id>
        </element-citation>
      </ref>
      <ref id="bib9">
        <element-citation publication-type="journal" id="sref9">
          <person-group person-group-type="author">
            <name>
              <surname>Emmerich</surname>
              <given-names>C.H.</given-names>
            </name>
            <name>
              <surname>Ordureau</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Strickson</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Arthur</surname>
              <given-names>J.S.</given-names>
            </name>
            <name>
              <surname>Pedrioli</surname>
              <given-names>P.G.</given-names>
            </name>
            <name>
              <surname>Komander</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Cohen</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Activation of the canonical IKK complex by K63/M1-linked hybrid ubiquitin chains</article-title>
          <source>Proc. Natl. Acad. Sci. USA</source>
          <volume>110</volume>
          <year>2013</year>
          <fpage>15247</fpage>
          <lpage>15252</lpage>
          <pub-id pub-id-type="pmid">23986494</pub-id>
        </element-citation>
      </ref>
      <ref id="bib10">
        <element-citation publication-type="journal" id="sref10">
          <person-group person-group-type="author">
            <name>
              <surname>Fiil</surname>
              <given-names>B.K.</given-names>
            </name>
            <name>
              <surname>Gyrd-Hansen</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Met1-linked ubiquitination in immune signalling</article-title>
          <source>FEBS J.</source>
          <volume>281</volume>
          <year>2014</year>
          <fpage>4337</fpage>
          <lpage>4350</lpage>
          <pub-id pub-id-type="pmid">25060092</pub-id>
        </element-citation>
      </ref>
      <ref id="bib11">
        <element-citation publication-type="journal" id="sref11">
          <person-group person-group-type="author">
            <name>
              <surname>Gerlach</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Cordier</surname>
              <given-names>S.M.</given-names>
            </name>
            <name>
              <surname>Schmukle</surname>
              <given-names>A.C.</given-names>
            </name>
            <name>
              <surname>Emmerich</surname>
              <given-names>C.H.</given-names>
            </name>
            <name>
              <surname>Rieser</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Haas</surname>
              <given-names>T.L.</given-names>
            </name>
            <name>
              <surname>Webb</surname>
              <given-names>A.I.</given-names>
            </name>
            <name>
              <surname>Rickard</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Anderton</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Wong</surname>
              <given-names>W.W.</given-names>
            </name>
          </person-group>
          <article-title>Linear ubiquitination prevents inflammation and regulates immune signalling</article-title>
          <source>Nature</source>
          <volume>471</volume>
          <year>2011</year>
          <fpage>591</fpage>
          <lpage>596</lpage>
          <pub-id pub-id-type="pmid">21455173</pub-id>
        </element-citation>
      </ref>
      <ref id="bib12">
        <element-citation publication-type="journal" id="sref12">
          <person-group person-group-type="author">
            <name>
              <surname>Haas</surname>
              <given-names>T.L.</given-names>
            </name>
            <name>
              <surname>Emmerich</surname>
              <given-names>C.H.</given-names>
            </name>
            <name>
              <surname>Gerlach</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Schmukle</surname>
              <given-names>A.C.</given-names>
            </name>
            <name>
              <surname>Cordier</surname>
              <given-names>S.M.</given-names>
            </name>
            <name>
              <surname>Rieser</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Feltham</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Vince</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Warnken</surname>
              <given-names>U.</given-names>
            </name>
            <name>
              <surname>Wenger</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Recruitment of the linear ubiquitin chain assembly complex stabilizes the TNF-R1 signaling complex and is required for TNF-mediated gene induction</article-title>
          <source>Mol. Cell</source>
          <volume>36</volume>
          <year>2009</year>
          <fpage>831</fpage>
          <lpage>844</lpage>
          <pub-id pub-id-type="pmid">20005846</pub-id>
        </element-citation>
      </ref>
      <ref id="bib13">
        <element-citation publication-type="journal" id="sref13">
          <person-group person-group-type="author">
            <name>
              <surname>Harhaj</surname>
              <given-names>E.W.</given-names>
            </name>
            <name>
              <surname>Dixit</surname>
              <given-names>V.M.</given-names>
            </name>
          </person-group>
          <article-title>Regulation of NF-ÎºB by deubiquitinases</article-title>
          <source>Immunol. Rev.</source>
          <volume>246</volume>
          <year>2012</year>
          <fpage>107</fpage>
          <lpage>124</lpage>
          <pub-id pub-id-type="pmid">22435550</pub-id>
        </element-citation>
      </ref>
      <ref id="bib14">
        <element-citation publication-type="journal" id="sref14">
          <person-group person-group-type="author">
            <name>
              <surname>Hitomi</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Christofferson</surname>
              <given-names>D.E.</given-names>
            </name>
            <name>
              <surname>Ng</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Yao</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Degterev</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Xavier</surname>
              <given-names>R.J.</given-names>
            </name>
            <name>
              <surname>Yuan</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Identification of a molecular signaling network that regulates a cellular necrotic cell death pathway</article-title>
          <source>Cell</source>
          <volume>135</volume>
          <year>2008</year>
          <fpage>1311</fpage>
          <lpage>1323</lpage>
          <pub-id pub-id-type="pmid">19109899</pub-id>
        </element-citation>
      </ref>
      <ref id="bib15">
        <element-citation publication-type="journal" id="sref15">
          <person-group person-group-type="author">
            <name>
              <surname>Ikeda</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Deribe</surname>
              <given-names>Y.L.</given-names>
            </name>
            <name>
              <surname>SkÃ¥nland</surname>
              <given-names>S.S.</given-names>
            </name>
            <name>
              <surname>Stieglitz</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Grabbe</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Franz-Wachtel</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>van Wijk</surname>
              <given-names>S.J.</given-names>
            </name>
            <name>
              <surname>Goswami</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Nagy</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Terzic</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>SHARPIN forms a linear ubiquitin ligase complex regulating NF-ÎºB activity and apoptosis</article-title>
          <source>Nature</source>
          <volume>471</volume>
          <year>2011</year>
          <fpage>637</fpage>
          <lpage>641</lpage>
          <pub-id pub-id-type="pmid">21455181</pub-id>
        </element-citation>
      </ref>
      <ref id="bib16">
        <element-citation publication-type="journal" id="sref16">
          <person-group person-group-type="author">
            <name>
              <surname>Iwai</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Fujita</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Sasaki</surname>
              <given-names>Y.</given-names>
            </name>
          </person-group>
          <article-title>Linear ubiquitin chains: NF-ÎºB signalling, cell death and beyond</article-title>
          <source>Nat. Rev. Mol. Cell Biol.</source>
          <volume>15</volume>
          <year>2014</year>
          <fpage>503</fpage>
          <lpage>508</lpage>
          <pub-id pub-id-type="pmid">25027653</pub-id>
        </element-citation>
      </ref>
      <ref id="bib17">
        <element-citation publication-type="journal" id="sref17">
          <person-group person-group-type="author">
            <name>
              <surname>Kirisako</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Kamei</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Murata</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Kato</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Fukumoto</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Kanie</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Sano</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Tokunaga</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Tanaka</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Iwai</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>A ubiquitin ligase complex assembles linear polyubiquitin chains</article-title>
          <source>EMBO J.</source>
          <volume>25</volume>
          <year>2006</year>
          <fpage>4877</fpage>
          <lpage>4887</lpage>
          <pub-id pub-id-type="pmid">17006537</pub-id>
        </element-citation>
      </ref>
      <ref id="bib18">
        <element-citation publication-type="journal" id="sref18">
          <person-group person-group-type="author">
            <name>
              <surname>Kovalenko</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Chable-Bessia</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Cantarella</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>IsraÃ«l</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Wallach</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Courtois</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination</article-title>
          <source>Nature</source>
          <volume>424</volume>
          <year>2003</year>
          <fpage>801</fpage>
          <lpage>805</lpage>
          <pub-id pub-id-type="pmid">12917691</pub-id>
        </element-citation>
      </ref>
      <ref id="bib19">
        <element-citation publication-type="journal" id="sref19">
          <person-group person-group-type="author">
            <name>
              <surname>Kupka</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Reichert</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Draber</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Walczak</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Formation and removal of poly-ubiquitin chains in the regulation of tumor necrosis factor-induced gene activation and cell death</article-title>
          <source>FEBS J.</source>
          <volume>283</volume>
          <year>2016</year>
          <fpage>2626</fpage>
          <lpage>2639</lpage>
          <pub-id pub-id-type="pmid">26749412</pub-id>
        </element-citation>
      </ref>
      <ref id="bib20">
        <element-citation publication-type="journal" id="sref20">
          <person-group person-group-type="author">
            <name>
              <surname>Ling</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Soares</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Croitoru</surname>
              <given-names>D.O.</given-names>
            </name>
            <name>
              <surname>Tattoli</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Carneiro</surname>
              <given-names>L.A.</given-names>
            </name>
            <name>
              <surname>Boniotto</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Benko</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Philpott</surname>
              <given-names>D.J.</given-names>
            </name>
            <name>
              <surname>Girardin</surname>
              <given-names>S.E.</given-names>
            </name>
          </person-group>
          <article-title>Post-transcriptional inhibition of luciferase reporter assays by the Nod-like receptor proteins NLRX1 and NLRC3</article-title>
          <source>J.Â Biol. Chem.</source>
          <volume>287</volume>
          <year>2012</year>
          <fpage>28705</fpage>
          <lpage>28716</lpage>
          <pub-id pub-id-type="pmid">22718770</pub-id>
        </element-citation>
      </ref>
      <ref id="bib21">
        <element-citation publication-type="journal" id="sref21">
          <person-group person-group-type="author">
            <name>
              <surname>Mathis</surname>
              <given-names>B.J.</given-names>
            </name>
            <name>
              <surname>Lai</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Qu</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Janicki</surname>
              <given-names>J.S.</given-names>
            </name>
            <name>
              <surname>Cui</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>CYLD-mediated signaling and diseases</article-title>
          <source>Curr. Drug Targets</source>
          <volume>16</volume>
          <year>2015</year>
          <fpage>284</fpage>
          <lpage>294</lpage>
          <pub-id pub-id-type="pmid">25342597</pub-id>
        </element-citation>
      </ref>
      <ref id="bib22">
        <element-citation publication-type="journal" id="sref22">
          <person-group person-group-type="author">
            <name>
              <surname>Moquin</surname>
              <given-names>D.M.</given-names>
            </name>
            <name>
              <surname>McQuade</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>F.K.</given-names>
            </name>
          </person-group>
          <article-title>CYLD deubiquitinates RIP1 in the TNFÎ±-induced necrosome to facilitate kinase activation and programmed necrosis</article-title>
          <source>PLoS ONE</source>
          <volume>8</volume>
          <year>2013</year>
          <fpage>e76841</fpage>
          <pub-id pub-id-type="pmid">24098568</pub-id>
        </element-citation>
      </ref>
      <ref id="bib23">
        <element-citation publication-type="journal" id="sref23">
          <person-group person-group-type="author">
            <name>
              <surname>Newton</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Manning</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Necroptosis and Inflammation</article-title>
          <source>Annu. Rev. Biochem.</source>
          <volume>85</volume>
          <year>2016</year>
          <fpage>743</fpage>
          <lpage>763</lpage>
          <pub-id pub-id-type="pmid">26865533</pub-id>
        </element-citation>
      </ref>
      <ref id="bib24">
        <element-citation publication-type="journal" id="sref24">
          <person-group person-group-type="author">
            <name>
              <surname>OâDonnell</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Perez-Jimenez</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Oberst</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Ng</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Massoumi</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Xavier</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Green</surname>
              <given-names>D.R.</given-names>
            </name>
            <name>
              <surname>Ting</surname>
              <given-names>A.T.</given-names>
            </name>
          </person-group>
          <article-title>Caspase 8 inhibits programmed necrosis by processing CYLD</article-title>
          <source>Nat. Cell Biol.</source>
          <volume>13</volume>
          <year>2011</year>
          <fpage>1437</fpage>
          <lpage>1442</lpage>
          <pub-id pub-id-type="pmid">22037414</pub-id>
        </element-citation>
      </ref>
      <ref id="bib25">
        <element-citation publication-type="journal" id="sref25">
          <person-group person-group-type="author">
            <name>
              <surname>Onisto</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Slongo</surname>
              <given-names>L.M.</given-names>
            </name>
            <name>
              <surname>Graziotto</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Zotti</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Negro</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Merico</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Moro</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Foresta</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Evidence for FSH-dependent upregulation of SPATA2 (spermatogenesis-associated protein 2)</article-title>
          <source>Biochem. Biophys. Res. Commun.</source>
          <volume>283</volume>
          <year>2001</year>
          <fpage>86</fpage>
          <lpage>92</lpage>
          <pub-id pub-id-type="pmid">11322771</pub-id>
        </element-citation>
      </ref>
      <ref id="bib26">
        <element-citation publication-type="journal" id="sref26">
          <person-group person-group-type="author">
            <name>
              <surname>Peltzer</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Rieser</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Taraborrelli</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Draber</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Darding</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Pernaute</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Shimizu</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Sarr</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Draberova</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Montinaro</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>HOIP deficiency causes embryonic lethality by aberrant TNFR1-mediated endothelial cell death</article-title>
          <source>Cell Rep.</source>
          <volume>9</volume>
          <year>2014</year>
          <fpage>153</fpage>
          <lpage>165</lpage>
          <pub-id pub-id-type="pmid">25284787</pub-id>
        </element-citation>
      </ref>
      <ref id="bib27">
        <element-citation publication-type="journal" id="sref27">
          <person-group person-group-type="author">
            <name>
              <surname>Reiley</surname>
              <given-names>W.W.</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Jin</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Losiewicz</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Donohue</surname>
              <given-names>K.B.</given-names>
            </name>
            <name>
              <surname>Norbury</surname>
              <given-names>C.C.</given-names>
            </name>
            <name>
              <surname>Sun</surname>
              <given-names>S.C.</given-names>
            </name>
          </person-group>
          <article-title>Regulation of TÂ cell development by the deubiquitinating enzyme CYLD</article-title>
          <source>Nat. Immunol.</source>
          <volume>7</volume>
          <year>2006</year>
          <fpage>411</fpage>
          <lpage>417</lpage>
          <pub-id pub-id-type="pmid">16501569</pub-id>
        </element-citation>
      </ref>
      <ref id="bib28">
        <element-citation publication-type="journal" id="sref28">
          <person-group person-group-type="author">
            <name>
              <surname>Saggar</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Chernoff</surname>
              <given-names>K.A.</given-names>
            </name>
            <name>
              <surname>Lodha</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Horev</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Kohl</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Honjo</surname>
              <given-names>R.S.</given-names>
            </name>
            <name>
              <surname>Brandt</surname>
              <given-names>H.R.</given-names>
            </name>
            <name>
              <surname>Hartmann</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Celebi</surname>
              <given-names>J.T.</given-names>
            </name>
          </person-group>
          <article-title>CYLD mutations in familial skin appendage tumours</article-title>
          <source>J.Â Med. Genet.</source>
          <volume>45</volume>
          <year>2008</year>
          <fpage>298</fpage>
          <lpage>302</lpage>
          <pub-id pub-id-type="pmid">18234730</pub-id>
        </element-citation>
      </ref>
      <ref id="bib29">
        <element-citation publication-type="journal" id="sref29">
          <person-group person-group-type="author">
            <name>
              <surname>Schaeffer</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Akutsu</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Olma</surname>
              <given-names>M.H.</given-names>
            </name>
            <name>
              <surname>Gomes</surname>
              <given-names>L.C.</given-names>
            </name>
            <name>
              <surname>Kawasaki</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Dikic</surname>
              <given-names>I.</given-names>
            </name>
          </person-group>
          <article-title>Binding of OTULIN to the PUB domain of HOIP controls NF-ÎºB signaling</article-title>
          <source>Mol. Cell</source>
          <volume>54</volume>
          <year>2014</year>
          <fpage>349</fpage>
          <lpage>361</lpage>
          <pub-id pub-id-type="pmid">24726327</pub-id>
        </element-citation>
      </ref>
      <ref id="bib30">
        <element-citation publication-type="journal" id="sref30">
          <person-group person-group-type="author">
            <name>
              <surname>Sedger</surname>
              <given-names>L.M.</given-names>
            </name>
            <name>
              <surname>McDermott</surname>
              <given-names>M.F.</given-names>
            </name>
          </person-group>
          <article-title>TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants - past, present and future</article-title>
          <source>Cytokine Growth Factor Rev.</source>
          <volume>25</volume>
          <year>2014</year>
          <fpage>453</fpage>
          <lpage>472</lpage>
          <pub-id pub-id-type="pmid">25169849</pub-id>
        </element-citation>
      </ref>
      <ref id="bib31">
        <element-citation publication-type="journal" id="sref31">
          <person-group person-group-type="author">
            <name>
              <surname>Takiuchi</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Nakagawa</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Tamiya</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Fujita</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Sasaki</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Saeki</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Takeda</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Sawasaki</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Buchberger</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Kimura</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Iwai</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Suppression of LUBAC-mediated linear ubiquitination by a specific interaction between LUBAC and the deubiquitinases CYLD and OTULIN</article-title>
          <source>Genes Cells</source>
          <volume>19</volume>
          <year>2014</year>
          <fpage>254</fpage>
          <lpage>272</lpage>
          <pub-id pub-id-type="pmid">24461064</pub-id>
        </element-citation>
      </ref>
      <ref id="bib32">
        <element-citation publication-type="journal" id="sref32">
          <person-group person-group-type="author">
            <name>
              <surname>Tauriello</surname>
              <given-names>D.V.</given-names>
            </name>
            <name>
              <surname>Haegebarth</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Kuper</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Edelmann</surname>
              <given-names>M.J.</given-names>
            </name>
            <name>
              <surname>Henraat</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Canninga-van Dijk</surname>
              <given-names>M.R.</given-names>
            </name>
            <name>
              <surname>Kessler</surname>
              <given-names>B.M.</given-names>
            </name>
            <name>
              <surname>Clevers</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Maurice</surname>
              <given-names>M.M.</given-names>
            </name>
          </person-group>
          <article-title>Loss of the tumor suppressor CYLD enhances Wnt/beta-catenin signaling through K63-linked ubiquitination of Dvl</article-title>
          <source>Mol. Cell</source>
          <volume>37</volume>
          <year>2010</year>
          <fpage>607</fpage>
          <lpage>619</lpage>
          <pub-id pub-id-type="pmid">20227366</pub-id>
        </element-citation>
      </ref>
      <ref id="bib33">
        <element-citation publication-type="journal" id="sref33">
          <person-group person-group-type="author">
            <name>
              <surname>Tokunaga</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Nakagawa</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Nakahara</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Saeki</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Taniguchi</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Sakata</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Tanaka</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Nakano</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Iwai</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>SHARPIN is a component of the NF-ÎºB-activating linear ubiquitin chain assembly complex</article-title>
          <source>Nature</source>
          <volume>471</volume>
          <year>2011</year>
          <fpage>633</fpage>
          <lpage>636</lpage>
          <pub-id pub-id-type="pmid">21455180</pub-id>
        </element-citation>
      </ref>
      <ref id="bib34">
        <element-citation publication-type="journal" id="sref34">
          <person-group person-group-type="author">
            <name>
              <surname>Trompouki</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Hatzivassiliou</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Tsichritzis</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Farmer</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Ashworth</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Mosialos</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members</article-title>
          <source>Nature</source>
          <volume>424</volume>
          <year>2003</year>
          <fpage>793</fpage>
          <lpage>796</lpage>
          <pub-id pub-id-type="pmid">12917689</pub-id>
        </element-citation>
      </ref>
      <ref id="bib35">
        <element-citation publication-type="journal" id="sref35">
          <person-group person-group-type="author">
            <name>
              <surname>Wagner</surname>
              <given-names>S.A.</given-names>
            </name>
            <name>
              <surname>Satpathy</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Beli</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Choudhary</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>SPATA2 links CYLD to the TNF-Î± receptor signaling complex and modulates the receptorÂ signaling outcomes</article-title>
          <source>EMBO J.</source>
          <year>2016</year>
          <fpage>e201694300</fpage>
          <pub-id pub-id-type="pmid">27307491</pub-id>
        </element-citation>
      </ref>
      <ref id="bib36">
        <element-citation publication-type="journal" id="sref36">
          <person-group person-group-type="author">
            <name>
              <surname>Walczak</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Iwai</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Dikic</surname>
              <given-names>I.</given-names>
            </name>
          </person-group>
          <article-title>Generation and physiological roles of linear ubiquitin chains</article-title>
          <source>BMC Biol.</source>
          <volume>10</volume>
          <year>2012</year>
          <fpage>23</fpage>
          <pub-id pub-id-type="pmid">22420778</pub-id>
        </element-citation>
      </ref>
      <ref id="bib37">
        <element-citation publication-type="journal" id="sref37">
          <person-group person-group-type="author">
            <name>
              <surname>Wertz</surname>
              <given-names>I.E.</given-names>
            </name>
          </person-group>
          <article-title>TNFR1-activated NF-ÎºB signal transduction: regulation by the ubiquitin/proteasome system</article-title>
          <source>Curr. Opin. Chem. Biol.</source>
          <volume>23</volume>
          <year>2014</year>
          <fpage>71</fpage>
          <lpage>77</lpage>
          <pub-id pub-id-type="pmid">25461388</pub-id>
        </element-citation>
      </ref>
      <ref id="bib38">
        <element-citation publication-type="journal" id="sref38">
          <person-group person-group-type="author">
            <name>
              <surname>Wright</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Reiley</surname>
              <given-names>W.W.</given-names>
            </name>
            <name>
              <surname>Chang</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Jin</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>A.J.</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Sun</surname>
              <given-names>S.C.</given-names>
            </name>
          </person-group>
          <article-title>Regulation of early wave of germ cell apoptosis and spermatogenesis by deubiquitinating enzyme CYLD</article-title>
          <source>Dev. Cell</source>
          <volume>13</volume>
          <year>2007</year>
          <fpage>705</fpage>
          <lpage>716</lpage>
          <pub-id pub-id-type="pmid">17981138</pub-id>
        </element-citation>
      </ref>
      <ref id="bib39">
        <element-citation publication-type="journal" id="sref39">
          <person-group person-group-type="author">
            <name>
              <surname>Yau</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Rape</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>The increasing complexity of the ubiquitin code</article-title>
          <source>Nat. Cell Biol.</source>
          <volume>18</volume>
          <year>2016</year>
          <fpage>579</fpage>
          <lpage>586</lpage>
          <pub-id pub-id-type="pmid">27230526</pub-id>
        </element-citation>
      </ref>
      <ref id="bib40">
        <element-citation publication-type="journal" id="sref40">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Stirling</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Temmerman</surname>
              <given-names>S.T.</given-names>
            </name>
            <name>
              <surname>Ma</surname>
              <given-names>C.A.</given-names>
            </name>
            <name>
              <surname>Fuss</surname>
              <given-names>I.J.</given-names>
            </name>
            <name>
              <surname>Derry</surname>
              <given-names>J.M.</given-names>
            </name>
            <name>
              <surname>Jain</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Impaired regulation of NF-kappaB and increased susceptibility to colitis-associated tumorigenesis in CYLD-deficient mice</article-title>
          <source>J.Â Clin. Invest.</source>
          <volume>116</volume>
          <year>2006</year>
          <fpage>3042</fpage>
          <lpage>3049</lpage>
          <pub-id pub-id-type="pmid">17053834</pub-id>
        </element-citation>
      </ref>
      <ref id="bib41">
        <element-citation publication-type="journal" id="sref41">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>A.J.</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Sun</surname>
              <given-names>S.-C.</given-names>
            </name>
          </person-group>
          <article-title>Regulation of antiviral innate immunity by deubiquitinase CYLD</article-title>
          <source>Cell. Mol. Immunol.</source>
          <volume>8</volume>
          <year>2011</year>
          <fpage>502</fpage>
          <lpage>504</lpage>
          <pub-id pub-id-type="pmid">21946435</pub-id>
        </element-citation>
      </ref>
      <ref id="bib42">
        <element-citation publication-type="journal" id="sref42">
          <person-group person-group-type="author">
            <name>
              <surname>Zinngrebe</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Montinaro</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Peltzer</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Walczak</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Ubiquitin in the immune system</article-title>
          <source>EMBO Rep.</source>
          <volume>15</volume>
          <year>2014</year>
          <fpage>28</fpage>
          <lpage>45</lpage>
          <pub-id pub-id-type="pmid">24375678</pub-id>
        </element-citation>
      </ref>
    </ref-list>
    <sec id="app2" sec-type="supplementary-material">
      <title>Supplemental Information</title>
      <p>
        <supplementary-material content-type="local-data" id="mmc1">
          <caption>
            <title>Table S1. HOIP-TAP, Analyzed by Mass Spectrometry, Related to FigureÂ 1A</title>
            <p>HOIP-deficient K562 cells were reconstituted with TAP-tagged HOIP-WT, enzymatically inactive HOIP-C885S, or vector control. HOIP-containing complexes were purified and analyzed by mass spectrometry.</p>
          </caption>
          <media xlink:href="mmc1.xlsx"/>
        </supplementary-material>
        <supplementary-material content-type="local-data" id="mmc2">
          <caption>
            <title>Table S2. TNFR1-SC Purification, Analyzed by Mass Spectrometry, Related to FigureÂ 1B</title>
            <p>TNFR1-SC purification from A549 cells using TAP-TNF [500ng/ml]. Control cells were left untreated. Protein complexes were analyzed using mass spectrometry.</p>
          </caption>
          <media xlink:href="mmc2.xlsx"/>
        </supplementary-material>
      </p>
    </sec>
    <ack id="ack0010">
      <title>Acknowledgments</title>
      <p>We thank the UCL Cancer Instituteâs Cancer Genome Engineering Facility, supported by the BRC, and the Welton Foundation and the Cancer Research UK-UCL Centre (515818) for providing technical support in CRISPR engineering and the Crick Peptide Synthesis Science Technology Platform. This work was supported by a Wellcome Trust Senior Investigator Award (508528), an ERC advanced grant (511254), a CRUK programme grant (A17341), a BRC Genome Editing Grant (511491), and the Francis Crick Institute (grant FCI01), which receives its core funding from Cancer Research UK, the UK Medical Research Council, and the Wellcome Trust (K.R.).</p>
    </ack>
    <fn-group>
      <fn id="app1" fn-type="supplementary-material">
        <p>Supplemental Information includes two tables and can be found with this article online at <ext-link ext-link-type="doi" xlink:href="10.1016/j.celrep.2016.07.086" id="intref0010">http://dx.doi.org/10.1016/j.celrep.2016.07.086</ext-link>.</p>
      </fn>
    </fn-group>
  </back>
  <floats-group>
    <fig id="fig1">
      <label>FigureÂ 1</label>
      <caption>
        <p>SPATA2 Constitutively Interacts with LUBAC and Forms Part of the Native TNFR1-SC</p>
        <p>(A) HOIP-deficient K562 cells were reconstituted with TAP-tagged wild-type (WT) HOIP or enzymatically inactive HOIP-C885S. HOIP-containing complexes were purified and analyzed by mass spectrometry.</p>
        <p>(B) TNFR1-SC was purified from A549 cells using TAP-TNF (500Â ng/ml). Protein complexes were analyzed by mass spectrometry.</p>
        <p>(C) Samples were prepared as in (A) and subjected to western blot analysis.</p>
        <p>(D) U937 cells were stimulated with FLAG-TNF (500Â ng/ml) for the indicated time. TNFR1-SC was purified using anti-FLAG beads and analyzed by western blotting.</p>
      </caption>
      <graphic xlink:href="gr1"/>
    </fig>
    <fig id="fig2">
      <label>FigureÂ 2</label>
      <caption>
        <p>SPATA2 Is Recruited to the TNFR1-SC and NOD2-SC via HOIP</p>
        <p>(A) WT or HOIP-deficient A549 cells were stimulated with FLAG-TNF (500Â ng/ml) for the indicated times. TNFR1-SC was purified and analyzed by western blotting.</p>
        <p>(B) HOIP-deficient A549 cells were reconstituted with either HOIP-WT or HOIP-CS, and TNFR1-SC was purified as in (A).</p>
        <p>(C) Wild-type (WT) or HOIP-deficient A549 cells were stably transfected with NOD2-TAP, stimulated with L18-MDP (200Â ng/ml) for the indicated times, and analyzed by western blotting.</p>
      </caption>
      <graphic xlink:href="gr2"/>
    </fig>
    <fig id="fig3">
      <label>FigureÂ 3</label>
      <caption>
        <p>Binding of CYLD to HOIP and Its Recruitment to the TNFR1-SC Requires SPATA2</p>
        <p>(A) HOIP, CYLD, or OTULIN were knocked out via clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 and levels of the indicated proteins compared to HeLa WT by western blot analysis.</p>
        <p>(B) ITC characterization of the interactions between (A) the HOIP-PUB domain (597Â Î¼M) and a peptide derived from the PIM motif (58Â Î¼M) of OTULIN and (B) the HOIP-PUB domain (398Â Î¼M) and the CYLD-USP domain (40Â Î¼M). For each titration, the raw data and normalized integrated heats are reported.</p>
        <p>(C) HEK293 cells were transfected with different combinations of CYLD, SPATA2, and OTULIN together with FLAG-HOIP. Protein complexes were subsequently purified using anti-FLAG beads and analyzed by western blotting.</p>
        <p>(D) SPATA2 expression was suppressed in FLAG-HOIP transfected HEK293 cells using siRNA. FLAG-HOIP was subsequently immunoprecipitated and tested for associated proteins by western blot analysis.</p>
        <p>(E) A549 cells were transfected with control or SPATA2 siRNA. After 72Â hr, cells were subjected to TNFR1-SC purification and analyzed by western blotting.</p>
      </caption>
      <graphic xlink:href="gr3"/>
    </fig>
    <fig id="fig4">
      <label>FigureÂ 4</label>
      <caption>
        <p>A PIM in SPATA2 Interacts with the PUB Domain of HOIP, whereas Its N Terminus Binds to CYLD</p>
        <p>(A) HOIP-deficient K562 cells reconstituted with vector control, FLAG-HOIP-WT, or different truncated versions of FLAG-HOIP were lysed and subjected to immunoprecipitation (IP) of HOIP. Samples were subsequently analyzed by western blotting.</p>
        <p>(B) HOIP-deficient A549 cells were reconstituted with HOIP-WT or HOIP-N102A. Cells were stimulated with FLAG-TNF and the resulting signaling complexes subsequently purified using anti-FLAG IP. Samples were analyzed by western blotting.</p>
        <p>(C) Truncated forms of GFP-SPATA2 were expressed in HEK293 cells. Following anti-GFP IP, SPATA association with HOIP and CYLD was evaluated by western blot analysis.</p>
        <p>(D) Peptide arrays representing amino acids 200â520 of SPATA2 as a series of 20-mer overlapping peptides, shifted by one, blotted on nitrocellulose membranes. The OTULIN PIM peptide served as a positive control. One membrane was incubated with recombinant GST-only (GST) the other one with GST-tagged PUB-domain of HOIP (GST-PUB). Bound GST-containing protein was subsequently detected by HRP immunofluorescence, and the signal of both membranes was overlaid.</p>
        <p>(E) ITC characterization of the interaction between HOIP-PUB domain (500Â Î¼M) and a peptide (50Â Î¼M) derived from the C-terminal region of SPATA2 (RGTYFSTQDDVDLYTDSEPR). The raw data and normalized integrated heats are reported.</p>
        <p>(F) Sequence alignment of the SPATA2 PIM region in different species. Underlined sequence indicates the peptide used in (E). Dr, <italic>Danio rerio</italic>; Cm, <italic>Chelonia mydas</italic>; Ap, <italic>Anas platyrhynchos</italic>; Gg, <italic>Gallus gallus</italic>; Mm, <italic>Mus musculus</italic>; Oa, <italic>Ovis aries</italic>; Ec, <italic>Equus caballus</italic>; Pt, <italic>Pan troglodytes</italic>; Hs, <italic>Homo sapiens</italic>.</p>
      </caption>
      <graphic xlink:href="gr4"/>
    </fig>
    <fig id="fig5">
      <label>FigureÂ 5</label>
      <caption>
        <p>SPATA2 Deficiency Reduces TNF-Induced Necroptosis but Has Minor Effects on TNF-Mediated Gene Activation</p>
        <p>(A) SPATA2 levels were reduced by siRNA in HeLa WT and HeLa CYLD-KO cells. Cells were then stimulated with TNF for the indicated time, lysed, and subjected to western blot analysis.</p>
        <p>(B) Knockdown of SPATA2 was performed in A549 by siRNA. Cells were then stimulated with TNF for the indicated time, lysed, and subjected to western blot analysis.</p>
        <p>(C) Bone-marrow-derived macrophages were isolated from CYLD-deficient mice or wild-type littermates. Cells were then stimulated with TNF and analyzed by western blotting.</p>
        <p>(D) SPATA2 or CYLD expression in L929 was silenced by siRNA. Cells were stimulated with 20Â ng/ml TNF and the indicated inhibitors. After 16Â hr, cells were collected, stained with propidium iodide, and measured by fluorescence-activated cell sorting (FACS). Data are presented as mean Â± SEM (nÂ = 3); <sup>ââ</sup>pÂ &lt; 0.01, statistics were performed using a two-tailed, unpaired Studentâs t test.</p>
        <p>(E) Representative western blot analysis of the knockdown efficiency in L929 cells used in the experiment shown in (D).</p>
      </caption>
      <graphic xlink:href="gr5"/>
    </fig>
  </floats-group>
</article>

</metadata></record></GetRecord></OAI-PMH>